Article Sidebar
Keywords:
Kasabach-Merritt Syndrome Microangiopathic hemolytic anemia Thrombocytopenia Consumption coagulopathy
Article Details
Issue
Section
Articles
Copyright is owned by Dr. Arun Kumar Agnihotri
Main Article Content
Vincristine: A new treatment option for Kasabach-Merritt Syndrome
Abstract
Kasabach-Merritt syndrome (KMS) is characterized by a rapidly enlarging
hemangioma, thrombocytopenia, microangiopathic hemolytic anemia and consumption coagulopathy as a result of platelet and red blood cell trapping and activation of clotting system within the vasculature of hemangioma. This syndrome is shown to be associated with kaposiform hemangioendotheliomas or tufted hemangioma.
hemangioma, thrombocytopenia, microangiopathic hemolytic anemia and consumption coagulopathy as a result of platelet and red blood cell trapping and activation of clotting system within the vasculature of hemangioma. This syndrome is shown to be associated with kaposiform hemangioendotheliomas or tufted hemangioma.
